Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diaziquone + procarbazine
- Development stage
- Preclinical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intraperitoneal (preclinical Studies), Oral (procarbazine), Intravenous Or Other Routes Possible Depending On Formulation/study Design
01
Overview
Diaziquone (AZQ, NSC 182986) is an antineoplastic agent with activity against primary nervous system tumors, including gliomas and medulloblastomas. Procarbazine (PCB, NSC 77213) is an alkylating agent used in combination chemotherapy for certain brain tumors. The combination of diaziquone and procarbazine has been studied preclinically in human glioma xenograft models in athymic mice, where it demonstrated enhanced therapeutic effects compared to either drug alone. Specifically, this combination produced significant increases in median growth delay and the number of tumor regressions compared to single-agent therapy[1][2]. The mechanism of action for diaziquone involves DNA alkylation/crosslinking leading to cell cycle arrest and apoptosis; procarbazine also acts as a DNA alkylator but may additionally inhibit protein, RNA, and DNA synthesis[3][4].
- Other names
- diaziquone and procarbazineAZQ and PCB
02
Targets
DNA
Beyond the preview
Go deeper on diaziquone + procarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diaziquone + procarbazine.